Journal of Pharmacy Practice and Research

Journal Information
ISSN / EISSN : 1445937X / 20552335
Current Publisher: Wiley (10.1002)
Total articles ≅ 1,645
Current Coverage
SCOPUS
Filter:

Latest articles in this journal

Daniel Lim, Anthony Hall, Margaret Jordan, Benita Suckling, Penelope H. Tuffin, Kristin Tynan, Namita Warrior, Courtney Munro
Journal of Pharmacy Practice and Research, Volume 49, pp 270-284; doi:10.1002/jppr.1550

Chris Alderman
Journal of Pharmacy Practice and Research, Volume 49, pp 205-206; doi:10.1002/jppr.1574

Rohan A. Elliott
Journal of Pharmacy Practice and Research, Volume 49, pp 207-209; doi:10.1002/jppr.1575

Prerna Varma, Melinda L. Jackson, Hailey Meaklim
Journal of Pharmacy Practice and Research, Volume 49, pp 209-211; doi:10.1002/jppr.1578

Michael Joseph Dooley
Journal of Pharmacy Practice and Research, Volume 49, pp 285-288; doi:10.1002/jppr.1579

Deirdre Criddle
Journal of Pharmacy Practice and Research, Volume 49, pp 288-290; doi:10.1002/jppr.1580

Megan J. Ehret
Journal of Pharmacy Practice and Research, Volume 49, pp 206-207; doi:10.1002/jppr.1570

Journal of Pharmacy Practice and Research, Volume 49, pp 203-204; doi:10.1002/jppr.1473

Ian D. Coombes
Journal of Pharmacy Practice and Research, Volume 49, pp 305-309; doi:10.1002/jppr.1585

Daniel W. O'brien, Menino O. Cotta, Lyn Choo, Stephen Fowler, Maria Downey, Stephanie Fisquet, Ivy Tan, Jason A. Roberts
Journal of Pharmacy Practice and Research; doi:10.1002/jppr.1529

Abstract:Dexmedetomidine is used in the intensive care unit (ICU) as a short‐term sedative. The data included in the manufacturer's product information is controversial, and there is little consensus to guide initial dosing and titration. This observational study surveyed the practice of dexmedetomidine use in Australian ICUs. An expression of interest (EOI) for a multisite observational study was sent to members of the ICU email group of the Society of Hospital Pharmacists Australia (SHPA). Participating members collected treatment‐related data for patients meeting inclusion criteria between January 2013 and July 2014. Six of 14 sites that responded positively to the EOI returned complete datasets, and 232 patients met the inclusion criteria. The main reported indications for dexmedetomidine use across the six sites were to manage agitation (33.2%), to aid extubation (32.8%) and to sedate (34.0%). The median duration of therapy was 42 h (range 1–672 h). Only nine patients (3.9%) received loading doses. The median maximum dose used for maintenance therapy in patients ranged from 1.2 to 4.0 microgram/kg per h. There was a significant disparity of practice across sites, as evidenced by differences in reported indication, off‐label use, rates of loading doses and doses used for maintenance therapy. Consensus prescribing guidelines are required to guide more consistent and evidence‐based prescribing of dexmedetomidine.